O-(2-ethylhexyl) O,O-tert-pentyl peroxycarbonate

Developmental toxicity / teratogenicity

Administrative data

Endpoint:

developmental toxicity

Type of information:

experimental study

Adequacy of study:

key study

Study period:

Experimental start date: 20 September 2017 Experimental completion date: 22 March 2018

Reliability:

1 (reliable without restriction)

Rationale for reliability incl. deficiencies:

guideline study

Data source

Reference

Reference Type:

study report

Title:

Unnamed

Year:

2018

Report date:

2018

Materials and methods

Test guideline

Qualifier:

according to guideline

Guideline:

other: OECD 421 guideline for testing of chemicals adopted 29 July 2016: Reproduction/developmental toxicity screening test.

Deviations:

no

GLP compliance:

yes (incl. QA statement)

Limit test:

no

Test material

Test material information

Constituent 1

Reference substance name:

O-(2-ethylhexyl) O,O-tert-pentyl peroxycarbonate

EC Number:

274-919-2

EC Name:

O-(2-ethylhexyl) O,O-tert-pentyl peroxycarbonate

Cas Number:

70833-40-8

Molecular formula:

C14H28O4

IUPAC Name:

2-ethylhexyl (1,1-dimethylpropylperoxy)formate

Test material form:

liquid

Details on test material:

As described in the report

Specific details on test material used for the study:

Test item: O-(2-ethylhexyl) O,O-tert-pentyl peroxycarbonate
Test item identity (including alternative names): tert-Amylperoxy-2-ethylhexylcarbonate
Trigonox 131
CAS number: 70833-40-8
Intended use: Industrial chemical
Appearance: Clear colorless liquid
Storage conditions: Frozen (-10 to -30C) in the dark
Supplier: Sponsor
Batch number: 1702442114
Retest date: 24 March 2019
Purity: 96.5%
Supplier’s responsibilities: Characterization of the test item and the documentation of the methods of synthesis, fabrication or derivation and stability.
Archive sample: A 0.5 mL representative sample was taken, placed in a well closed glass container and stored in the archives under the same conditions as the bulk material.

Test animals

Species:

rat

Strain:

Wistar

Details on test animals or test system and environmental conditions:

Strain/Species RccHan™;WIST rat.
Supplier Envigo RMS (UK) Limited.
Number of animals ordered 44 males and 48 females (92 in total; included 4 spare males and 8 spare females)
Spare animals were removed from the study room after treatment commenced.

Duration of acclimatization
Males: six days before commencement of treatment.
Females: 20 days before commencement of treatment.

Age of the animals at the start of treatment
Males: 84 to 90 days old.
Females: 98 to 104 days old.

Weight range of the animals at the start of treatment
Males: 319 to 358 g.
Females: 199 to 227 g.

Allocation and Identification
Allocation On arrival and non-selective allocation to cages.

Estrous cycles were evaluated pre-treatment. After 14 days evaluation, animals that failed to exhibit typical 4-5 days cycles were not allocated to the study.
On Day 1 of study all animals were weighed and body weights were reviewed before dosing commenced to ensure variations in body weight of animals did not exceed 20% of the mean for each sex.

Groups were adjusted to reduce inter-/intra-group variation.

Identification of animals Each adult animal was assigned a number and identified uniquely within the study by a tail tattoo before Day 1 of treatment. The offspring were numbered individually within each litter on Day 1 of age, using a toe tattoo.

Identification of cages Each cage label was color-coded according to group and was numbered uniquely with cage and study number, as well as the identity of the occupant(s).

Animal Replacement
Before the commencement of treatment, study allocation was revised to reduce inter/intra group body weight variation by replacement of animals with spares and moving animals within groups. Any individuals rejected during the acclimatization period were replaced with spare animals of suitable weight from the same batch.

Animal Care and Husbandry
Environmental Control

Rodent facility
Limited access - to minimize entry of external biological and chemical agents and to minimize the transference of such agents between rooms.

Air supply Filtered fresh air which was passed to atmosphere and not recirculated.

Temperature and relative humidity Monitored and maintained within the range of 20-24ºC and 40-70%.
There were no deviations from these ranges.

Lighting Artificial lighting, 12 hours light : 12 hours dark.
Electricity supply Public supply with automatic stand-by generators.

Animal Accommodation
Cages Cages comprised of a polycarbonate body with a stainless steel mesh lid; changed at appropriate intervals.
Solid (polycarbonate) bottom cages were used during the acclimatization, pre-pairing, treatment, gestation, littering and lactation periods.
Grid bottomed cages were used during pairing for mating; these were suspended above absorbent paper which was changed daily.

Cage distribution The cages were distributed on the racking to equalize, as far as possible, environmental influences amongst the groups.

Bedding Solid bottom cages contained softwood based bark-free fiber bedding, which was changed at appropriate intervals each week.

Number of animals per cage
Pre-pairing up to four animals of one sex
Pairing one male and one female
Males after mating up to four animals
Gestation one female
Lactation one female + litter

Environmental Enrichment
Aspen chew block A soft white untreated wood block; provided to each cage throughout the study (except during pairing and lactation) and replaced when necessary.
Polycarbonate shelter Provided to each cage throughout the study (except during pairing and lactation) and replaced at the same time as the cages.

Diet Supply
Diet SDS VRF1 Certified pelleted diet.
A sample (100g) of each batch of diet used was retained within Pharmacy (frozen -10 to -30ºC) and discarded after finalization of the report.
The diet contained no added antibiotic or other chemotherapeutic or prophylactic agent.
Availability Non-restricted.

Water Supply
Supply Potable water from the public supply via polycarbonate bottles with sipper tubes. Bottles were changed at appropriate intervals.
Availability Non-restricted.

Administration / exposure

Route of administration:

oral: gavage

Vehicle:

other: PEG300

Details on exposure:

Correction factor
Used as supplied; no correction factor applied.

Vehicle PEG300.

Method of preparation
O-(2-ethylhexyl) O,O-tert-pentyl peroxycarbonate was prepared for administration as a series of graded concentrations in the vehicle. Starting with the low concentration (50 mg/mL), the formulation was prepared by weighing out the required amount of test item, adding 40 to 50% of the final volume of vehicle and magnetically stirring until all the test item was uniformly mixed. The solution was made up to the required volume with the vehicle and stirred using a magnetic stirrer until homogenous.

The procedure was repeated for the mid and high dose (50 and 200 mg/mL).

Frequency of preparation
Weekly.

Storage of formulation
Refrigerated (2-8ºC).

Test item accounting
Detailed records of compound usage were maintained. The amount of test item necessary to prepare the formulations and the amount actually used were determined on each occasion. The difference between these amounts was checked before the formulations were dispensed.

Analytical verification of doses or concentrations:

yes

Details on analytical verification of doses or concentrations:

Formulation Analysis

Validated concentration range
20 mg/mL to 200 mg/mL
GLP Study: Harlan Laboratories Study Report: D45837 (homogeneity and stability establish for 4 hours at ambient temperature and 8 days refrigerated storage); 10 mg/mL validated as part of this study.
Stability assessment Before commencement of treatment, the suitability of the proposed mixing procedures was determined and specimen formulations at a concentration of 10 mg/mL were analyzed to assess the stability and homogeneity of the test item in the liquid matrix.

Achieved concentration
Samples of each formulation prepared for administration during the first and last week of treatment were analyzed for achieved concentration of the test item.

Preparation of Calibration Standards
A primary standard solution (1000 μg/mL) was prepared by dissolving an accurately weighed quantity (ca. 50 mg) of O-(2-ethylhexyl)O,O-tert-pentyl peroxycarbonate in acetonitrile (50 mL).

Solutions for instrument calibration were prepared by appropriate dilution of the primarystandard using diluent and contained O-(2-ethylhexyl)O,O-tert-pentyl peroxycarbonate at nominal concentrations of 50 μg/mL, 100 μg/mL, 150 μg/mL, 200 μg/mL and 250 μg/mL.

Calibration solutions were injected onto the HPLC, at the beginning and end of each sample analysis sequence as a minimum, using the conditions detailed in the chromatographic section.

Preparation of Test Samples
A representative sample of test formulation (1 mL, accurate volume or weight where applicable) was dissolved in a suitable volume of acetonitrile. The extract was diluted using diluent to provide a solution containing O-(2-ethylhexyl)O,O-tert-pentyl peroxycarbonate at an expected concentration within the range 100 μg/mL to 200 μg/mL.

The concentration of O-(2-ethylhexyl)O,O-tert-pentyl peroxycarbonate in the final solution was quantified by HPLC using UV detection.

Preparation of Recovery Samples
Procedural recoveries were prepared by fortifying samples (1 mL) of control matrix (PEG300) with known amounts of O-(2-ethylhexyl)O,O-tert-pentyl peroxycarbonate. The prepared procedural recoveries were analyzed in accordance with the analytical procedure.

Instrumentation parameters
High performance liquid chromatograph (HPLC): Waters Alliance 2695 separation module and 2487 dual wavelength detector
Column: XBridge Shield RP18, 75 × 4.6 mm, 3.5 μm
Column temperature: 45ºC
Sample temperature: 4ºC
Mobile Phase: ACN/water/ o-H3PO4 65/35/0.1 v/v/v
Flow rate: 1 mL/min
Needle wash: ACN/water 50/50 v/v
Detector wavelength: UV, 210 nm
Injection volume: 20 μL
Run time: 8 minutes
Approximate retention time: 4.3 minutes

Details on mating procedure:

Mating Procedure
Paired for mating After two weeks of treatment.
Male/female ratio 1:1 from within the same treatment groups.
Duration of pairing Up to two weeks.
Daily checks for evidence of mating Ejected copulation plugs in cage tray and sperm in the vaginal smear.
Day 0 of gestation When positive evidence of mating was detected.
Male/female separation Day when mating evidence was detected.
Pre-coital interval Calculated for each female as the time between first pairing and evidence of mating.
3.6.6 Parturition Observations and Gestation Length
Duration of gestation Time elapsing between the detection of mating and commencement of parturition.
Parturition observations From Day 20 after mating, females were inspected three times daily for evidence of parturition. The progress and completion of parturition was monitored, numbers of live and dead offspring were recorded and any difficulties observed were recorded.

Duration of treatment / exposure:

Males were treated daily for two weeks before pairing, up to necropsy after a minimum of four consecutive weeks. Females were treated daily for two weeks before pairing, throughout pairing, gestation and until Day 12 of lactation.

Frequency of treatment:

Daily

Duration of test:

Males were treated daily for two weeks before pairing, up to necropsy after a minimum of four consecutive weeks. Females were treated daily for two weeks before pairing, throughout pairing, gestation and until Day 12 of lactation.

Doses / concentrations

Doses / concentrations 1

Dose / conc.:

50 mg/kg bw/day (actual dose received)

Doses / concentrations 2

Dose / conc.:

250 mg/kg bw/day (actual dose received)

Doses / concentrations 3

Dose / conc.:

1 000 mg/kg bw/day (actual dose received)

No. of animals per sex per dose:

10 males
10 females

Control animals:

yes, concurrent vehicle

Details on study design:

Rationale for Dose Level Selection
Dose levels of 50, 250 and 1000 mg/kg/day were selected in conjunction with the Sponsor based on the findings from an OECD 407 study conducted at 100, 300 and 1000 mg/kg/day (Harlan Laboratories Study Report D45837). In this study findings included:

• Reductions in food consumption at 1000 mg/kg/day
• Slightly high liver weights for females at 300 or 1000 mg/kg/day, with two animals exhibiting minimal centrilobular hepatocellular hypertrophy; considered to be metabolic adaption and therefore not adverse.
• Increased severity of hyaline droplets in the renal proximal tubules of males at 1000 mg/kg/day; this is considered to be an adverse finding in rats but has no toxicological significance in man.
• Forestomach mucosal necrosis for males at 100 mg/kg/day and for both sexes at 300 mg/kg/day or 1000 mg/kg/day; these were considered to be local injuries that resulted in subsequent adverse reactions.

It was therefore concluded that the no-observed-adverse-effect-level (NOAEL) for systemic toxicity was 1000 mg/kg/day. However the no-observed-effect-level (NOEL) and the local no-observed-adverse-effect-level (NOAEL) were considered to be below 100 mg/kg/day, based on the adverse irritative findings in the forestomach.

On this study a high dose of 1000 mg/kg/day was anticipated to elicit parental effects in terms of food consumption, liver pathology and stomach lesions. A low dose of 50 mg/kg/day was selected with the aim to establish a NOEL, with an intermediate dose of 250 mg/kg/day to aid interpretation of any dose response.

Examinations

Maternal examinations:

Serial Observations
Clinical Observations
Animals were inspected visually at least twice daily for evidence of ill-health or reaction to treatment. Cages were inspected daily for evidence of animal ill-health amongst the occupant(s). Any deviation from normal was recorded at the time in respect of nature and severity, date and time of onset, duration and progress of the observed condition, as appropriate.

During the acclimatization period, observations of the animals and their cages were recorded at least once per day.

Signs Associated with Dosing
Detailed observations were performed to establish and confirm a pattern of signs in association with dosing according to the following schedule:

F0 females
Week 1 - daily
Week 2 - once

Gestation phase - Days 0, 7, 14 and 20
Lactation phase - Days 1, 6 and 12

Detailed observations were recorded at the following times in relation to dose administration:
Pre-dose
One to two hours after completion of dosing
As late as possible in the working day

Clinical Signs
A detailed physical examination was performed on each animal to monitor general health according to the following schedule:

F0 females Once each week until pairing
Gestation phase - Days 0, 7, 14 and 20
Lactation phase - Days 1, 7 and 13

Body Weight
The weight of animals was recorded as follows:

F0 females Weekly during acclimatization.
Before dosing on the day that treatment commenced (Week 0) and weekly before mating.
Days 0, 7, 14 and 20 after mating.
Day 1, 4, 7 and 13 of lactation.
On the day of necropsy.

Food Consumption
The weight of food supplied to each cage, that remaining and an estimate of any spilled was recorded as follows:

F0 animals
Weekly, before pairing.
For females after mating food consumption was performed to match the body weight recording:
Days 0-6, 7-13 and 14-19 after mating
Days 1-3, 4-6 and 7-12 of lactation.

From these records the mean weekly or daily consumption per animal (g/animal/week or g/animal/day) was calculated for each relevant phase.

Estrous Cycles
Dry and wet smears were taken as follows:
Dry smears For 15 days before pairing using cotton swabs.
Wet smears Using pipette lavage during the following phases:
For 14 days before treatment (all females including spares); animals that failed to exhibit 4-5 day cycles were not allocated to study.

After pairing until mating.

For four days before scheduled termination (nominally Days 10-13 of lactation).

Thyroid Hormone Analysis
Blood samples were collected as follows:
At termination All surviving F0 adult males and females (no samples were obtained from animals which failed to litter or with litter death).

Terminal Investigations
Time of Necropsy

F0 females failing to produce a viable litter Day 25 after mating.
F0 females whose litter died before Day 13 On or after day the last offspring died.
F0 females Day 13 of lactation.

Necropsy
All adult animals were subject to a detailed necropsy. After a review of the history of each animal, a full macroscopic examination of the tissues was performed. All external features and orifices were examined visually. Any abnormality in the appearance or size of any organ and tissue (external and cut surface) was recorded and the required tissue samples preserved in appropriate fixative.

The organs weighed, tissue samples fixed and sections examined microscopically are detailed as follows for adult animals:
Tissue and regions examined

Abnormalities
Epididymides (caput, corpus and cauda)
Ovaries
Pituitary
Prostate
Seminal vesicles (with coagulation gland)
Stomach
Thyroid
Uterus with cervix and oviducts

Ovaries and uterine content:

Duration of gestation
Time elapsing between the detection of mating and commencement of parturition.

Parturition observations
From Day 20 after mating, females were inspected three times daily for evidence of parturition. The progress and completion of parturition was monitored, numbers of live and dead offspring were recorded and any difficulties observed were recorded.

The following were recorded:
Each uterine horn Number of implantation sites was counted and confirmed if none were visible at visual inspection for non-pregnant females.
For apparently empty uterine horns The absence of uterine implantation sites was confirmed by
staining with ammonium sulphide [modification of the
Salewski staining technique (Salewski, E, 1964)].

Female whose litter died before Day 13 of lactation Mammary tissue appearance.

Fetal examinations:

Clinical observations
Examined at approximately 24 hours after birth (Day 1 of age) and then daily thereafter for evidence of ill health or reaction to maternal treatment; these were on an individual offspring basis or for the litter as a whole, as appropriate.

Litter size
Daily records were maintained of mortality and consequent changes in litter size from Days 1-13 of age.
Sex ratio of each litter Recorded on Days 1, 4, 7 and 13 of age.
Individual offspring body weights Days 1, 4, 7 and 13 of age.
Ano-genital distance Day 1 - all offspring.
Nipple/areolae count Day 13 of age - male offspring.


Thyroid Hormone Analysis
Blood samples were collected as follows:

Day 4 of age F1 offspring, two females per litter (where possible).
• one for T4 (serum)#
• one for TSH (plasma)
No females were allocated to these procedures if:
• The resultant live litter size fell below eight offspring.
• The resultant number of live females fell to less than three
If only four female offspring were available in a litter but the overall litter size was more than eight, one female pup was selected with priority given to the serum sample.
# priority was given to serum sample

Day 13 of age F1 offspring, two males and two females per litter (where possible).
- two for T4 (serum): where possible one male and one female#
- two for TSH (plasma): where possible one male and one female
# priority given to serum sample

Premature deaths
Where possible, a fresh macroscopic examination (external and internal) with an assessment of stomach for milk content was performed.
F1 offspring on Day 13 of age All animals were subject to an external macroscopic examination; particular attention was paid to the external genitalia. Abnormal offspring were retained in appropriate fixative.
Thyroid glands were preserved from two offspring - one male and one female in each litter, where possible.

Statistics:

Please refer to "Any other information on materials and methods incl. tables"

Indices:

Mating Performance & Fertility

Group values were calculated for males and females separately for the following:

Percentage mating (%) = (No. of animals mating / Animals paired) x 100

Conception rate (%) = (No. of animals achieving pregnancy / Animals mated) x 100

Fertility index (%) = (No. of animals achieving pregnancy / Animals paired) x 100

Gestation Length and Index
Gestation length was calculated as the number of gestation days up to and including the day on which offspring were first observed, with Day 1 = day of mating for calculation purposes. Where parturition had started overnight, this value was adjusted by subtracting half of one day. Gestation index was calculated for each group as:

Gestation index (%) = (No. of live litters born / Number pregnant) x 100

Results and discussion

Results: maternal animals

General toxicity (maternal animals)

Clinical signs:

no effects observed

Description (incidence and severity):

No signs were observed in association with dose administration and there were no signs at routine physical examination that could be related to administration of the test item.

Mortality:

no mortality observed

Body weight and weight changes:

effects observed, non-treatment-related

Description (incidence and severity):

Body weight change for females during Week 1 of treatment was slightly low at 250 and 1000 mg/kg/day at approximately 57% of Controls; however this difference did not attain statistical significance. The overall weight gain for females for the two weeks before pairing, during gestation and lactation were unaffected by treatment at dose levels up to and including 1000 mg/kg/day.

Food consumption and compound intake (if feeding study):

effects observed, non-treatment-related

Description (incidence and severity):

During the first week of treatment females at 1000 mg/kg/day had slightly but not statistically significant low food consumption, approximately 89% of Controls. At 50 and 250 mg/kg/day food consumption was similar to Controls.
During gestation food consumption was considered unaffected by treatment.
During lactation the overall food consumption for females receiving 1000 mg/kg/day was marginally low when compared with Controls (approximately 93% of Controls), however the mean phase values were not statistically different from Controls.

Food efficiency:

not examined

Water consumption and compound intake (if drinking water study):

not examined

Ophthalmological findings:

not examined

Haematological findings:

not examined

Clinical biochemistry findings:

not examined

Urinalysis findings:

not examined

Behaviour (functional findings):

not examined

Immunological findings:

not examined

Organ weight findings including organ / body weight ratios:

no effects observed

Gross pathological findings:

no effects observed

Description (incidence and severity):

Effects were only obersved in the stomachs of males

Neuropathological findings:

not examined

Histopathological findings: non-neoplastic:

effects observed, treatment-related

Description (incidence and severity):

There were treatment-related findings in the stomach of one female that received 250 mg/kg/day and one female that received 1000 mg/kg/day.

Histopathological findings: neoplastic:

not examined

Other effects:

no effects observed

Description (incidence and severity):

Thyroid Hormone Analysis
In general, all samples from adult males at termination and Day 13 of age male and female offspring from the animals in Groups 1 to 4 had concentrations that were comparable with endogenous levels observed in the control matrix used to prepare the QC samples. No further analyses were required.

Maternal developmental toxicity

Number of abortions:

not examined

Description (incidence and severity):

Not applicable, as rats do not abort.

Pre- and post-implantation loss:

effects observed, treatment-related

Description (incidence and severity):

The number of implantations and subsequently the live litter size on Days 1 and 4 of age (before selection of offspring for thyroid hormone sampling) were statistically significantly low at 1000 mg/kg/day when compared with concurrent Controls (implantations - p<0.01; litter size - p<0.05) and review of the historical control data showed that two litters on Day 4 were outside the 90 percentile range (7.7-14.4; n=74) . Litter size at 50 or 250 mg/kg/day was unaffected by parental treatment.

Total litter losses by resorption:

no effects observed

Early or late resorptions:

no effects observed

Dead fetuses:

no effects observed

Changes in pregnancy duration:

no effects observed

Changes in number of pregnant:

no effects observed

Other effects:

no effects observed

Effect levels (maternal animals)

1

Key result

Dose descriptor:

NOAEL

Remarks:

Reproductive performance

Effect level:

250 mg/kg bw/day (actual dose received)

Based on:

test mat.

Basis for effect level:

pre and post implantation loss

2

Key result

Dose descriptor:

NOEL

Remarks:

Parental effects

Effect level:

50 mg/kg bw/day (actual dose received)

Based on:

test mat.

Basis for effect level:

other: acroscopic and microscopic changes in the stomach of parental animals at 250 and 1000 mg/kg/day.

3

Key result

Dose descriptor:

NOAEL

Remarks:

Parental effects

Effect level:

1 000 mg/kg bw/day (actual dose received)

Based on:

test mat.

Basis for effect level:

other: an overall parental NOAEL of 1000 mg/kg/day.

Results (fetuses)

Fetal body weight changes:

effects observed, non-treatment-related

Description (incidence and severity):

At 1000 mg/kg/day body weight gain for male offspring from Day 4 to 7 of age was statistically significantly low when compared with Controls (p<0.05; approximately 83% of Controls). Female offspring at the same dose level showed marginally low weight gain over the same period (91 % of Controls), however this difference did not attain statistical significance. Offspring body weight gain from Day 7 to Day 13 of age and the overall weight gain from Day 1 to Day 13 of age was similar across the groups. Therefore this slight effect on offspring bodyweight gain at 1000 mg/kg/day was not considered to be adverse

Reduction in number of live offspring:

effects observed, treatment-related

Description (incidence and severity):

• Low implantations and subsequent live litter size on Days 1 and 4 of age at 1000 mg/kg/day.

Changes in sex ratio:

no effects observed

Changes in litter size and weights:

effects observed, treatment-related

Description (incidence and severity):

The number of implantations and subsequently the live litter size on Days 1 and 4 of age (before selection of offspring for thyroid hormone sampling) were statistically significantly low at 1000 mg/kg/day when compared with concurrent Controls (implantations - p<0.01; litter size - p<0.05). Litter size at 50 or 250 mg/kg/day was unaffected by parental treatment.

Changes in postnatal survival:

no effects observed

External malformations:

no effects observed

Skeletal malformations:

not examined

Visceral malformations:

not examined

Other effects:

effects observed, non-treatment-related

Description (incidence and severity):

. In general, all samples from adult males at termination and Day 13 of age male and female offspring from the animals in Groups 1 to 4 had concentrations that were comparable with endogenous levels observed in the control matrix used to prepare the QC samples. No further analyses were required.

At 1000 mg/kg/day one litter comprising of 13 offspring was found dead prior to Day 1 of age (litter no 140); the offspring weighed between 4.4 and 5.3 g. Macroscopic examination of the dam (no. 140) revealed 13 uterine implantation sites and pale/inactive mammary tissue. In the absence of any effect on offspring survival in the remaining litters this isolated litter death is considered to be unrelated to parental treatment.

Effect levels (fetuses)

Key result

Dose descriptor:

NOAEL

Remarks:

Offspring development

Effect level:

250 mg/kg bw/day (actual dose received)

Based on:

test mat.

Sex:

not specified

Basis for effect level:

reduction in number of live offspring

Overall developmental toxicity

Key result

Developmental effects observed:

yes

Lowest effective dose / conc.:

250 mg/kg bw/day (actual dose received)

Treatment related:

yes

Relation to maternal toxicity:

developmental effects occurring together with maternal toxicity effects, but not as a secondary non-specific consequence of maternal toxicity effects

Dose response relationship:

yes

Relevant for humans:

not specified

Applicant's summary and conclusion

Conclusions:

It was concluded that the no-observed-adverse-effect-level (NOAEL) for reproductive performance and offspring development based on the effect on implantation count is 250 mg/kg/day. The no-observed effect level (NOEL) for parental effects considering the local irritant effect is 50 mg/kg/day with an overall parental NOAEL of 1000 mg/kg/day.

Executive summary:

 Summary

This study was a screening test for reproductive/developmental effects, and assessment of endocrine disruptor relevant endpoints, with the administration of the test item [O‑(2‑ethylhexyl) O,O-tert-pentyl peroxycarbonate], an industrial chemical, by oral gavage, to Sprague Dawley rats for at least four weeks.

Three groups of ten male and ten female rats received test item at doses of 50, 250 or 1000 mg/kg/day by oral gavage administration. Males were treated daily for two weeks before pairing, up to necropsy after a minimum of four consecutive weeks. Females were treated daily for two weeks before pairing, throughout pairing, gestation and until Day 12 of lactation. Females were allowed to litter, rear their offspring and were killed on Day 13 of lactation. The F1 generation received no direct administration of the test item; any exposure was in utero or via the milk. A similarly constituted Control group received the vehicle, PEG300, at the same volume dose as treated groups.

During the study, clinical condition, body weight, food consumption, thyroid hormone analysis, estrous cycles, pre-coital interval, mating performance, fertility, gestation

length, organ weight and macroscopic pathology and histopathology investigations were undertaken.

The clinical condition, litter size and survival, sex ratio, body weight, ano-genital distance and macropathology for all offspring were also assessed. Nipple counts were performed on male offspring on Day 13 of age.

Results and Conclusion

Treatment ofO-(2-ethylhexyl) O,O-tert-pentyl peroxycarbonate to parental animals at 50, 250 or 100 mg/kg/day for two weeks before pairing, during pairing and then up to termination of the males after 4 weeks of treatment and females on Day 13 of lactation was generally well tolerated. There was no adverse effect on parental clinical condition, body weight performance, food consumption, estrous cycles, mating performance or fertility. The clinical condition, body weight and survival of the subsequent F1 offspring were also unaffected by parental treatment.

Treatment related findings were restricted to:

·        Low implantations and subsequent live litter size on Days 1 and 4 of age at 1000 mg/kg/day. This effect was slight and in isolation with no effects on any other reproductive parameters or micropathology of the reproductive organs.

·        Macroscopic and microscopic changes in the stomach of parental animals at 250 and 1000 mg/kg/day. The microscopic findings of epithelial hyperplasia and submucosal infiltration of inflammatory cells in the non-glandular region of the stomach were considered to be indicative of a local irritant effect of the test item at 250 and 1000 mg/kg/day, with a dose-relationship in male animals; in males this correlated with gross findings of a thickened forestomach.

It was therefore concluded that the no-observed-adverse-effect-level (NOAEL) for reproductive performance and offspring development based on the effect on implantation count is 250 mg/kg/day. The no-observed effect level (NOEL) for parental effects considering the local irritant effect is 50 mg/kg/day with an overall parental NOAEL of 1000 mg/kg/day.